CAIRO: AstraZeneca Egypt is poised to significantly enhance its investment in the local pharmaceutical market, with plans to inject $50 million, representing nearly 50 per cent of the company’s capital.
The initiative by British pharma giant, as articulated by Country President Hatem Werdany, underscores the firm’s commitment to bolstering its operations in Egypt, where it has maintained a robust presence since 1968.
The company’s longstanding engagement in the manufacture and supply of essential medicines has been pivotal in improving healthcare outcomes for the Egyptian population.
Central to AstraZeneca Egypt’s expansion strategy is the ongoing development of its manufacturing facility located in Sixth of October.
Localisation plans
The company aims to increase its production capacity from a current maximum of 900 million tablets annually to an impressive 2.195 billion tablets by 2028.
The ambitious goal is indicative of the company’s dedication to meeting the growing demand for pharmaceuticals in the region. The factory currently operates with a packaging capacity of 51 million packages through four dedicated packaging lines, ensuring efficient distribution of its products.
Moreover, AstraZeneca Egypt is exploring the localisation of 80 per cent of its production units by 2028. The strategic move not only aims to enhance the availability of essential medicines but also reflects a broader commitment to fostering local industry and economic growth.
By doubling its investments and localising production, AstraZeneca is positioned to play a crucial role in strengthening the Egyptian healthcare system, ultimately making a tangible difference in the lives of millions of citizens.
